Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IL-13 inhibitor

- PMLiVE

GSK’s severe asthma therapy Nucala gets EU nod

Becomes the first IL-5 inhibitor to be approved in the EU

- PMLiVE

Meda collaborates on asthma comic book

Launches new Explain Asthma volume at ACAAI annual meeting

- PMLiVE

GSK bags FDA approval for severe asthma drug Nucala

Drug to be launched as soon as possible

- PMLiVE

CHMP backs GSK’s asthma antibody and Novartis’ heart failure drug

Positive opinions for GSK's IL-5 antibody and Novartis' potential $5bn-a-year brand

- PMLiVE

AZ and Ironwood to file IBS drug linaclotide in China next year

Phase III trial of linaclotide show it improved symptoms such as abdominal pain

- PMLiVE

AZ appoints Pam Cheng as executive VP, operations and IT

She joins from MSD China where she was president

- PMLiVE

AZ and Inserm collaborate on diabetes and kidney disease

Three-year partnership will look at new therapeutic approaches

- PMLiVE

AZ’s phase III gout data frustrates firm

Lesinurad discrepancies highlighted in clinical trials

Teva Pharma logo

Teva set for FDA verdict on reslizumab early next year

Ruling for severe asthma therapy Cinquil expected by March 2016

- PMLiVE

GSK’s new asthma biologic gains FDA panel backing

British firm looking to help shore up its ageing respiratory portfolio 

- PMLiVE

Receptos rejected AZ takeover bid, say sources

Sources also claim the Delaware-based firm is being chased by Gilead Sciences and Teva

- PMLiVE

Ardelyx buys back drug from AZ to ‘accelerate development’

The two firms have been working on the NHE3 inhibitor tenapanor since 2012

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links